Impel Pharmaceuticals Inc (NASDAQ: IMPL) has experienced a decline in its stock price by -12.68 compared to its previous closing price of 0.35. However, the company has seen a gain of 37.78% in its stock price over the last five trading days. InvestorPlace reported 2023-09-08 that Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.

Is It Worth Investing in Impel Pharmaceuticals Inc (NASDAQ: IMPL) Right Now?

, and the 36-month beta value for IMPL is at 0.78. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price suggested by analysts for IMPL is $40.00, which is $39.69 above the current market price. The public float for IMPL is 7.87M, and currently, shorts hold a 10.28% of that float. The average trading volume for IMPL on November 20, 2023 was 1.09M shares.

IMPL’s Market Performance

IMPL’s stock has seen a 37.78% increase for the week, with a 1.81% rise in the past month and a -10.66% fall in the past quarter. The volatility ratio for the week is 48.72%, and the volatility levels for the past 30 days are at 23.30% for Impel Pharmaceuticals Inc The simple moving average for the past 20 days is 19.45% for IMPL’s stock, with a -73.72% simple moving average for the past 200 days.

Analysts’ Opinion of IMPL

Many brokerage firms have already submitted their reports for IMPL stocks, with Wedbush repeating the rating for IMPL by listing it as a “Outperform.” The predicted price for IMPL in the upcoming period, according to Wedbush is $21 based on the research report published on May 18, 2021 of the previous year 2021.

IMPL Trading at -20.38% from the 50-Day Moving Average

After a stumble in the market that brought IMPL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.62% of loss for the given period.

Volatility was left at 23.30%, however, over the last 30 days, the volatility rate increased by 48.72%, as shares surge +10.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.33% lower at present.

During the last 5 trading sessions, IMPL rose by +37.78%, which changed the moving average for the period of 200-days by -90.86% in comparison to the 20-day moving average, which settled at $0.2610. In addition, Impel Pharmaceuticals Inc saw -91.73% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for IMPL

Current profitability levels for the company are sitting at:

The net margin for Impel Pharmaceuticals Inc stands at -840.28. The total capital return value is set at -182.79, while invested capital returns managed to touch -243.15. Equity return is now at value -2546.09, with -105.93 for asset returns.

When we switch over and look at the enterprise to sales, we see a ratio of 0.00, with the company’s debt to enterprise value settled at 0.66. The receivables turnover for the company is 2.87 and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.60.


In conclusion, Impel Pharmaceuticals Inc (IMPL) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.